Viking Therapeutics, Inc. (VKTX)

Over the past six months, Viking Therapeutics, Inc. (VKTX) stock has experienced fluctuations. As of February 6, 2026, the share price was $28.44. Looking back, the stock price on February 7, 2025, was $32.56, representing a decline of 12.65% over the year. The 52-week range for the stock has been between $18.92 and $43.15. Recent daily movements include a closing price of $28.44 on February 6, 2026, with a daily range of $26.89 to $28.47. On February 5, 2026, the stock closed at $26.29, down 11.06%. There was a notable increase of 8.18% on February 6, 2026. Retail investor attention has been observed, with rising retail chatter and message volume around VKTX stock more than tripling ahead of its Q4 earnings report, which is projected for February 10, 2026. The company also reported its Q3 2025 earnings on October 22, 2025, with an actual EPS of -0.810 USD, and Q2 2025 earnings on July 23, 2025, with an actual EPS of -0.580 USD.

As a clinical-stage biopharmaceutical company, Viking Therapeutics' revenue is driven by its ability to advance its pipeline through successful clinical trials and potential partnerships or licensing agreements rather than product sales. Therefore, traditional demand seasonality is not directly applicable to Viking Therapeutics at this stage.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for liver and metabolic diseases. Founded in 2012 and based in San Diego, CA, it operates in the Biotechnology & Medical Research industry. Its pipeline includes VK2809 for NASH and hypercholesterolemia, VK5211 for patients recovering from hip fracture surgery, VK0214 for X-linked adrenoleukodystrophy, and VK2735 for various metabolic disorders.

Viking Therapeutics, Inc. is headquartered in San Diego, California, United States. Its stock is listed on multiple international exchanges, including NASDAQ, Deutsche Boerse AG, London Stock Exchange, and Borsa Italiana, indicating a global reach for its investment opportunities.

Viking Therapeutics' brand reputation is tied to its scientific advancements and clinical trial results. Analyst sentiment suggests VK2735 may lack differentiation from existing obesity treatments, potentially impacting investor perception. No widespread events significantly affecting the company's overall brand reputation beyond typical clinical development challenges and market competition were identified in the past year.

Institutional shareholders hold approximately 63.02% of Viking Therapeutics' stock, with major holders including Vanguard Group Inc, Fmr Llc, and BlackRock, Inc. Individual investors own about 27.90% of the company, while insiders hold approximately 9.09%. Ligand Pharmaceuticals Inc is the largest individual shareholder, owning 5.15% of the company.